Citadel Advisors
VBIO

Citadel Advisors’s Valion Bio VBIO Stock Holding History

Citadel Advisors’s Portfolio VBIO Stock Details VBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-856
Closed -$5.63K – 15248
2024
Q2 		$5.63K Buy
+856
New +$10.8K ﹤0.01% 13384
2023
Q4 		– Sell
-982
Closed -$28.9K – 15261
2023
Q3 		$28.9K Buy
+982
New +$72.6K ﹤0.01% 12302

Other funds holding VBIO

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citadel Advisors's VBIO Position: Q3 2024 in Review

Citadel Advisors sold out of Valion Bio (VBIO) in Q3 2024, closing a stake of 856 shares — an estimated $5.63K sold.

Citadel Advisors first reported a position in VBIO in Q3 2023 and held it in 2 quarters. The position peaked at $28.9K in Q3 2023. 10 funds tracked by Wall St. Rank hold VBIO as of Q3 2024.

  • Citadel Advisors reported no remaining Valion Bio position as of Q3 2024 after selling out during the quarter.
  • Citadel Advisors sold 856 Valion Bio shares in Q3 2024, an estimated $5.63K.
  • Citadel Advisors first reported a position in Valion Bio in Q3 2023 and held it in 2 quarters.
  • Citadel Advisors's Valion Bio position peaked at $28.9K in Q3 2023.
  • 10 funds tracked by Wall St. Rank held Valion Bio as of Q3 2024.

Based on Citadel Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.